Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Weight Management
Vasculature-targeting peptide that selectively destroys adipose blood vessels.
Peptide B
Weight Management
Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials.
Typical vial
5 mg
Typical dose
Per kg dosing (research-only) mcg
Half-life
~hours
FDA status
Not FDA approved.
Typical vial
10 mg
Typical dose
300-6000 mcg
Half-life
~80-90 hours (once-weekly dosing)
FDA status
Not FDA approved. Investigational compound in phase 3 clinic…
FTPP-Adipotide effects
Survodutide effects
FTPP-Adipotide side effects
Survodutide side effects
FTPP-Adipotide dosing ranges
Animal research (rhesus monkey model)
0.43 mg/kg · Daily SubQ × 28 days · Per published protocol
Human self-experimentation
Not recommended · — · —
Survodutide dosing ranges
Obesity (phase 2/3 protocol)
0.3-6.0 mg · Once weekly SubQ (titrated) · Long-term (chronic dosing)
MASH / NASH (phase 2)
1.2-6.0 mg · Once weekly SubQ (titrated) · 48 weeks minimum
Type 2 diabetes (phase 2)
0.3-4.8 mg · Once weekly SubQ · Long-term
FTPP-Adipotide: Vasculature-targeting peptide that selectively destroys adipose blood vessels. Typical dose Per kg dosing (research-only) mcg. Survodutide: Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials. Typical dose 300-6000 mcg. Both fall under the Weight Management category.
Stacking FTPP-Adipotide with Survodutide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
FTPP-Adipotide is typically dosed: Daily SubQ × 28 days for Animal research (rhesus monkey model); — for Human self-experimentation. Survodutide is typically dosed: Once weekly SubQ (titrated) for Obesity (phase 2/3 protocol); Once weekly SubQ (titrated) for MASH / NASH (phase 2); Once weekly SubQ for Type 2 diabetes (phase 2).
FTPP-Adipotide: Not FDA approved. Survodutide: Not FDA approved. Investigational compound in phase 3 clinical trials for obesity and MASH/NASH.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free